Number of Shares and Voting Rights of Innate Pharma as of December 31, 2024

Rhea-AI Summary

Innate Pharma (Euronext Paris: IPH; Nasdaq: IPHA) has released its share and voting rights data as of December 31, 2024. The company reported 83,830,336 ordinary shares, along with 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

The total number of theoretical voting rights stands at 84,585,576, which includes voting rights attached to AGAP 2016 (130 voting rights for AGAP 2016-1 and 111 for AGAP 2016-2). The total number of exercisable voting rights is 84,567,001, calculated excluding treasury shares. No voting rights are attached to AGAP 2017.

Insights

Market Structure Analyst

This regulatory disclosure reveals Innate Pharma's capital structure with 83,830,336 ordinary shares and two classes of preferred shares totaling 14,075 units. The difference between theoretical (84,585,576) and exercisable (84,567,001) voting rights indicates a small treasury position of approximately 18,575 shares.

For a microcap biotech company with a market cap of $142M, this share structure is relatively complex with multiple share classes. The minimal treasury holdings suggest efficient capital management. The voting rights structure, particularly the enhanced voting power of AGAP 2016 preferred shares, creates a layered governance framework typical of French-listed companies but potentially less familiar to U.S. investors.

Think of this structure like a house with different types of keys - while most shareholders have regular keys (ordinary shares), some hold master keys (preferred shares) that carry extra privileges. This complexity can affect liquidity and trading dynamics, especially given the stock's dual listing on Euronext Paris and Nasdaq.

MARSEILLE, France--(BUSINESS WIRE)-- Regulatory News:

Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) releases its total number of shares outstanding as well as its voting rights as of December 31, 2024:

Total number of shares outstanding:	83,830,336	ordinary shares
	6,494	Preferred Shares 2016
	7,581	Preferred Shares 2017
Total number of theoretical voting rights (1):	84,585,576
Total number of exercisable voting rights (2):	84,567,001

(1) The total number of theoretical voting rights (or “gross” voting rights) is used as the basis for calculating the crossing of shareholding thresholds. In accordance with Article 223-11 of the AMF General Regulation, this number is calculated on the basis of all shares to which voting rights are attached, including shares whose voting rights have been suspended. The total number of theoretical voting rights includes voting rights attached to AGAP 2016, i.e. 130 voting rights for the AGAP 2016-1 and 111 voting rights for the AGAP 2016-2. No voting rights attached to AGAP 2017.

(2) The total number of exercisable voting rights (or “net” voting rights) is calculated without taking into account the shares held in treasury by the Company, with suspended voting rights. It is released so as to ensure that the market is adequately informed, in accordance with the recommendation made by the AMF on July 17, 2007.

About Innate Pharma

Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through three therapeutic approaches: multi-specific NK Cell Engagers via its ANKET^® (Antibody-based NK cell Engager Therapeutics) proprietary platform and Antibody Drug Conjugates (ADC) and monoclonal antibodies (mAbs).

Innate’s portfolio includes several ANKET^® drug candidates to address multiple tumor types as well as IPH4502 a differentiated ADC in development in solid tumors. In addition, anti-KIR3DL2 mAb lacutamab is developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, and anti-NKG2A mAb monalizumab is developed with AstraZeneca in non-small cell lung cancer.

Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients.

Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US.

Learn more about Innate Pharma at www.innate-pharma.com and follow us on LinkedIn and X.

Information about Innate Pharma shares

ISIN code Ticker code LEI

FR0010331421 Euronext: IPH Nasdaq: IPHA 9695002Y8420ZB8HJE29

Disclaimer on forward-looking information and risk factors

This press release contains certain forward-looking statements, including those within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. The use of certain words, including “anticipate,” “believe,” “can,” “could,” “estimate,” “expect,” “may,” “might,” “potential,” “expect” “should,” “will,” or the negative of these and similar expressions, is intended to identify forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties, which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company’s reliance on third parties to manufacture its product candidates, the Company’s commercialization efforts and the Company’s continued ability to raise capital to fund its development. For an additional discussion of risks and uncertainties, which could cause the Company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking statements, please refer to the Risk Factors (“Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (“AMF”), which is available on the AMF website http://www.amf-france.org or on Innate Pharma’s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (“SEC”), including the Company’s Annual Report on Form 20-F for the year ended December 31, 2023, and subsequent filings and reports filed with the AMF or SEC, or otherwise made public by the Company. References to the Company’s website and the AMF website are included for information only and the content contained therein, or that can be accessed through them, are not incorporated by reference into, and do not constitute a part of, this press release.

In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by the Company or any other person that the Company will achieve its objectives and plans in any specified time frame or at all. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250115246814/en/

For additional information, please contact:



Investors



Innate Pharma

Henry Wheeler

Tel.: +33 (0)4 84 90 32 88

Henry.wheeler@innate-pharma.fr



Media Relations



NewCap

Arthur Rouillé

Tel.: +33 (0)1 44 71 00 15

innate@newcap.eu

Source: Innate Pharma SA

FAQ

What is the total number of ordinary shares outstanding for Innate Pharma (IPHA) as of December 31, 2024?

Innate Pharma had 83,830,336 ordinary shares outstanding as of December 31, 2024.

How many preferred shares does Innate Pharma (IPHA) have as of December 31, 2024?

Innate Pharma has 6,494 Preferred Shares 2016 and 7,581 Preferred Shares 2017.

What is the difference between theoretical and exercisable voting rights for IPHA as of December 31, 2024?

The theoretical voting rights are 84,585,576, while exercisable voting rights are 84,567,001. The difference is due to treasury shares being excluded from exercisable voting rights.

How many voting rights are attached to IPHA's AGAP 2016 shares?

AGAP 2016 shares have 130 voting rights for AGAP 2016-1 and 111 voting rights for AGAP 2016-2.